ONKOS Molecular Diagnostics - Crunchbase Company Profile & Funding

Overview

ONKOS Molecular Diagnostics

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Events

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About ONKOS Molecular Diagnostics

CB Rank

472319

ONKOS functions to enable not only the best patient management available but also healthcare providers efficiencies and savings.

Founded

obfuscation

Private

Ribeirão, Sao Paulo, Brazil

1-10

www.onkos.com.br/

Biotechnology

Health Care

Medical

Wellness

Details

Legal Name

ONKOS Molecular Diagnostics LTD

Operating Status

Active

Company Type

For Profit

About the Company

Onkos functions to provide proprietary gene expression-based diagnostic tests that focused on providing answers to diagnostic uncertainties in Oncology. They deliver answers that give practical and objective support to clinical decision-making, providing better clinical management and improving the quality of life of the cancer patient.

Phone Number

+55 16 4141 5120

Contact Email

onkos@onkos.com.br

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

mir-THYpe full

A molecular classifier test for indeterminate thyroid nodules (Bethesda III or IV) that reclassifies nodules as benign or malignant to guide medical management and avoid unnecessary surgeries.

mir-THYpe pre-op

A preoperative molecular panel for thyroid nodules (Bethesda V or VI) that analyzes prognostic markers to assist in planning the extent and urgency of thyroid surgery.